Enhanced Dual-Action Immunotherapy in CAR-T Cells Boosts Control of B-ALL Progression
B-cell acute lymphoblastic leukemia (B-ALL) remains the most prevalent pediatric cancer, representing approximately 85% of all leukemia diagnoses in children. Despite significant advances in treatment,...